Search results
Recurrence Data for Narrow Band Imaging™ (NBI™) Technology Show Value in the Fight Against...
WKBN 27 Youngstown· 2 days ago"Without dyes, without any change to the patient's standard cystoscopy, and with only a push of a button, urologists can better visualize a lesion, and potentially contribute to reduced recurrence ...
US FDA approves ImmunityBio's bladder cancer therapy
AOL· 4 days ago(Reuters) -The U.S. health regulator approved on Monday ImmunityBio's combination therapy to treat a type of bladder cancer, marking an end to the company's ...
FDA OKs First IL-15 Receptor Agonist for Early Bladder Cancer
MedPage Today· 4 days agoThe FDA approved nogapendekin alfa inbakicept (Anktiva) for bacillus Calmette-Guérin...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 2 days agos Keytruda in patients with head and neck cancer. Overall, 27.3% responded to the treatment. A total...
Brachytherapy for Prostate Cancer Linked to Higher Risk of Second Pelvic Malignancy
MedPage Today· 4 days agoPelvic second malignancy occurred twice as often after brachytherapy for prostate cancer as compared...
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Zacks via Yahoo Finance· 12 hours agoApproval of better HIV treatments should strengthen the HIV franchise in the wake of the increasing...
U.K. Tests World-First Personalized Skin Cancer Vaccine
Forbes· 21 hours agoPersonalized with genetic information from a patient’s own tumor, vaccines like this could one day...
All-Over Itchy Skin (Without) Rash
Verywell Health via Yahoo News· 4 days agoPrompt diagnosis and treatment are important with any cancer. Medications Many medications—both prescription and OTC—can cause itching. Some supplements...
ImmunityBio Inc. Drug Approved By FDA
The Post-Journal· 2 days agoOn Monday, the Food and Drug Administration officially approved ANKTIVA, a treatment for unresponsive non-muscle invasive bladder cancer
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva
Morningstar· 4 days agoBy Colin Kellaher Shares of ImmunityBio jumped more than 25% in premarket trading Tuesday after the immunotherapy company received Food and Drug Administration approval of its Anktiva
